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Background: The first cases of extensively drug resist-
ant gonorrhoea were recorded in the United Kingdom 
in 2018. There is a public health need for strategies 
on how to deploy existing and novel antibiotics to 
minimise the risk of resistance development. As rapid 
point-of-care tests (POCTs) to predict susceptibil-
ity are coming to clinical use, coupling the introduc-
tion of an antibiotic with diagnostics that can slow 
resistance emergence may offer a novel paradigm 
for maximising antibiotic benefits. Gepotidacin is a 
novel antibiotic with known resistance and resistance-
predisposing mutations. In particular, a mutation 
that confers resistance to ciprofloxacin acts as the 
‘stepping-stone’ mutation to gepotidacin resistance. 
Aim: To investigate how POCTs detecting  Neisseria 
gonorrhoeae  resistance mutations for ciprofloxacin 
and gepotidacin can be used to minimise the risk of 
resistance development to gepotidacin. Methods: We 
use individual-based stochastic simulations to for-
mally investigate the aim. Results: The level of testing 
needed to reduce the risk of resistance development 
depends on the mutation rate under treatment and 
the prevalence of stepping-stone mutations. A POCT 
is most effective if the mutation rate under antibi-
otic treatment is no more than two orders of magni-
tude above the mutation rate without treatment and 
the prevalence of stepping-stone mutations is 1–13%. 
Conclusion: Mutation frequencies and rates should be 
considered when estimating the POCT usage required 
to reduce the risk of resistance development in a given 
population. Molecular POCTs for resistance mutations 
and stepping-stone mutations to resistance are likely 
to become important tools in antibiotic stewardship.
Introduction
Neisseria gonorrhoeae, the causal agent of the sexually 
transmitted infection (STI) gonorrhoea, is becoming 
increasingly resistant to available antibiotic treatment 
options [1,2]. The most widely recommended treatment 
for gonorrhoea is a combination therapy of ceftriaxone 
plus azithromycin, administered empirically without 
bacterial culture or point-of-care testing [3]. In isolates 
collected across Europe, the proportion of isolates 
with decreased susceptibility to ceftriaxone increased 
from 15% to 17.7% from 2015 to 2016. At the same time 
azithromycin resistance across Europe was stable at 
about 7% but was much higher in individual countries 
(34.5% in Portugal) [4]. The first treatment failure of 
this dual therapy was reported in the United Kingdom 
(UK) in 2014 [5]. Azithromycin resistance in combina-
tion with reduced susceptibility to ceftriaxone has 
been well-studied [4]. Resistance to previous recom-
mended treatments, such as ciprofloxacin, is generally 
high (30-70% in Europe, above 70% in East Asia) [2]. As 
ceftriaxone is at the same time the first-line and last-
resort treatment, the World Health Organization (WHO) 
in 2017 declared the possible evolution of untreatable 
gonorrhoea a global public health emergency [6].
In an attempt to spare ceftriaxone as a last-resort 
treatment, rapid point-of-care tests (POCTs) detecting 
ciprofloxacin resistance mutations have been devel-
oped. Thus, even though ciprofloxacin is no longer rec-
ommended for gonorrhoea treatment, it could still be 
used when a POCT detects no resistance mutations [7]. 
Such tests could easily be expanded to include known 
resistance markers for other antibiotics.
2 www.eurosurveillance.org
Gepotidacin is a novel topoisomerase IIA inhibitor cur-
rently under development and in phase III clinical trials 
with activity against N. gonorrhoeae [8]. Its mechanism 
of action differs from that of fluoroquinolones, and it 
has demonstrated activity against most ciprofloxacin-
resistant gonococcal strains [9]. Ciprofloxacin inhibits 
bacterial DNA gyrase and topoisomerase IV. The main 
ciprofloxacin resistance mutations in genes coding for 
DNA gyrase subunit A (GyrA) and topoisomerase IV 
subunit A (ParC) in  N. gonorrhoeae  are presented in 
the  Supplementary Material 1, Supplementary Table 
1. In a recent phase II clinical trial on the efficacy of 
gepotidacin against uncomplicated genitourinary gon-
orrhoea, emergence of resistance was observed for N. 
gonorrhoeae  isolates from two treatment failures 
following use of a single dose of 3g gepotidacin. This 
resistance is likely to have emerged due to the combi-
nation of a pre-existing ciprofloxacin resistance muta-
tion (D86N) in the parC gene and de novo within-host 
emergence of an A92T mutation in the gyrA gene (Table 
1). Additional experiments suggest that the gepotidacin 
minimum inhibitory concentration (MIC) is only signifi-
cantly increased if both mutations are present together 
[10].  See Supplementary Material 1, Supplementary 
Text 1  for more details on the microbiological analysis 
of the phase II clinical trial. Structural analysis of the 
interaction of gepotidacin with GyrA suggests that 
gepotidacin does not interact with the two quinolone 
binding sites in GyrA at amino acid positions 91 and 95 
[9]. Therefore, it was assumed that the S91F and D95G 
mutations in gyrA were not critical for the evolution of 
gepotidacin resistance. There may be other mutations 
that can cause resistance to gepotidacin, but they were 
not observed in the phase II clinical trial.
Novel post-treatment mutations occurred in isolates 
from two subjects that were treated with a single dose 
of 3g gepotidacin [11]. The mutations S91F and D95G 
in gyrA and D86N in parC on their own confer different 
levels of resistance to ciprofloxacin.
Here, we consider the novel paradigm of introducing 
an antibiotic together with a POCT to control gonococ-
cal infections and slow down resistance development. 
A POCT for gepotidacin resistance would determine 
if the known stepping-stone mutations,  gyrA  A92T 
or  parC  D86N, were present. If neither were detected, 
then gepotidacin could be used without substantial 
risk of treatment failure, based on current evidence, 
as there are no other known clinically relevant target-
specific resistance mutations for gepotidacin in  N. 
gonorrhoeae. If one or both mutations were present, 
treatment with another antibiotic would be indicated.
Determining the frequencies of resistance mutations 
requires surveillance systems such as the data recorded 
in the European Gonococcal Antimicrobial Surveillance 
Programme (Euro-GASP, data collection since 2009) 
and the US Gonococcal Isolate Surveillance Project 
database (GISP, data collection since 1986). Euro-GASP 
monitors  N. gonorrhoeae  antimicrobial susceptibility 
trends by phenotypically characterising isolates from 
male and female patients. GISP samples isolates from 
male patients attending STD clinics. Each participating 
country contributes 100 cultured and characterised 
isolates per year.
Our study aims to answer several questions using 
a theoretical modelling framework: can a molecular 
POCT that detects known stepping-stone mutations 
prevent the spread of gepotidacin-resistant strains? 
Under what conditions is a POCT most effective at 
reducing the risk of resistance development, and how 
frequently would such a test need to be used to reduce 
this risk by at least 50% over five years? These ques-
tions have broader implications for designing antibiotic 
stewardship strategies and prolonging the life span of 
novel and existing antibiotics.
Methods
Model framework
We developed a compartmental deterministic model 
framework of gonorrhoea transmission building on 
previous models [12,13]. As in Whittles et al. [14] our 
model uses transmission parameter values derived 
from men who have sex with men (MSM) populations in 
London. The model has three compartments, suscepti-
ble (S), infected (I) and treated (T) individuals (Figure 
1,  Supplementary Material 1, Supplementary Text 2). 
Individuals in the infected class are infected but not 
currently treated. Individuals in the treated class are 
infected and currently receiving treatment. The time 
Table 1
Genotypes of isolates at baseline and test-of-cure from gepotidacin treatment failures with emergence of resistance, phase II 
clinical trial, 2017 [11]
Participant number Visit Genotype gyrA Genotype parC MIC gepotidacin (mg/L)
MIC ciprofloxacin 
 
(mg/L)
4
Baseline S91F D95G D86N 1 8
Test-of-cure S91F A92T D95G D86N > 32 8
6
Baseline S91F D95G D86N 1 4
Test-of-cure S91F A92T D95G D86N 32 4
MIC: minimum inhibitory concentration.
Mutation gyrA A92T leading to gepotidacin resistance is displayed in bold.
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that individuals spend in the treated class is the dura-
tion for which the within-host antibiotic concentration 
is great enough to clear the infection.
The key novel feature of our model is that we explicitly 
consider different resistance genotypes of relevance to 
gepotidacin. Given that there are two known stepping-
stone mutations that together cause elevated MICs, 
susceptible individuals can be infected by one of four 
strains. If 0 signifies the sensitive allele and 1 the resist-
ant allele, these strains are: 00, 10, 01 and 11. Based 
on the observations from the phase II clinical study 
[15], we assume that only the 11 genotype is resistant 
to both ciprofloxacin and gepotidacin, whereas 10 and 
01 are resistant to ciprofloxacin only. The model also 
allows for the possibility that both resistance muta-
tions can arise de novo over the course of an infection.
Model parameters and transitions
Susceptible individuals become infected at rate β, 
which in our modelling framework is population-spe-
cific and depends on the sexual contact rate and the 
infection probability per contact (Table 2). Infected 
individuals seek treatment at rate γ and can recover 
spontaneously at rate f. Treated individuals recover 
at rate g if they are not resistant, and return to the 
susceptible class. Individuals with treatment fail-
ures are reclassified as infected. For more details on 
the model processes see  Supplementary Material 1, 
Supplementary Text 2. To assess the impact of uncer-
tainty in model parameters, we performed sensitivity 
analyses by varying model parameters across a range 
of measured values from the literature. We assume an 
annual incidence rate of gonorrhoea of 22,000 cases 
in a total population of 1.5 million individuals, approxi-
mating the MSM population in the UK [16]. We varied 
the starting conditions for each of the simulation sce-
narios described below. For model parameter and vari-
able values used in the simulations see Table 2.
Resistance evolution
Sensitive strains can acquire resistance to antibiotics 
by de novo mutations. The mutation rate in  N. gonor-
rhoeae has been determined from phylogenetic studies 
[17]. Several studies indicate that the mutation rate 
under treatment may be increased due to the SOS DNA 
damage response [18-20]. A DNA damage response sys-
tem in N. gonorrhoeae has been described by Schook et 
al. [21]. Other topoisomerase II inhibitors are known to 
increase the mutation rate by interfering with DNA rep-
lication [22,23]. However, as the mechanism of action 
of gepotidacin differs from that of conventional topoi-
somerase II inhibitors, it may not increase the muta-
tion rate to the same extent. There are no estimates 
for mutation rates in  N. gonorrhoeae  under antibiotic 
pressure. We therefore performed simulations for a 
range of mutation rate parameters under treatment 
based on estimates obtained from other bacterial 
species (Table 2).
N. gonorrhoeae  is known to have a high rate of 
homologous recombination [24]. Recombination 
between different gonococcal strains can only occur in 
mixed infections at the same anatomical site. Thus, the 
effective recombination rate can be calculated as:
coinfection frequency × ratio of recombination to muta-
tion × base mutation rate
The coinfection frequency with different gonococcal 
strains at the same anatomical site is unknown, but we 
can use the frequency of infections with different gono-
coccal strains at different anatomical sites as a proxy 
upper-bound estimate for the frequency of mixed infec-
tions (13%) at the same anatomical site [25]. The ratio 
of recombination to mutation events has been esti-
mated from whole genome sequence data (genome-
wide average) [17,26,27]. If we assume a mutation 
rate of 2.45 × 10 − 8  substitutions per nt per day and a 
recombination-to-mutation ratio of 2.2 [27], we obtain 
an effective recombination rate of 7 × 10 − 9. Since this 
would lead to an increase in the rate of resistance 
acquisition that is smaller than the increased muta-
tion rates that we tested, we do not explicitly consider 
recombination in the model.
Figure 1
Two-locus gonorrhoea antibiotic resistance model
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S: susceptible individuals; I: infected, untreated individuals; T: 
infected, treated individuals.
The basic model has three main compartments, susceptible, 
infected and treated individuals (i.e. infected individuals that are 
undergoing treatment). Individuals can be infected with one of 
four gonococcal strains that differ in the combination of resistance 
(‘stepping-stone’) mutations they carry (00, 10, 01 or 11). Only 
strains with both gepotidacin resistance mutations (11) are 
considered resistant to gepotidacin. Strains with one resistance 
mutation (10 and 01) are resistant to ciprofloxacin, but sensitive to 
gepotidacin. First subscript: state of resistance for the first locus 
(0 – sensitive, 1 – resistant); second subscript: state of resistance 
for the second locus (0 – sensitive, 1 – resistant); β: infection rate 
parameter (product of sexual contact rate and infection probability 
per contact); f: spontaneous recovery rate from infection without 
treatment (1/f – duration of natural infection); g: Cure rate in 
individuals currently being treated (1/g – duration of treatment); 
γ: treatment seeking rate (1/γ – time from start of infection to 
start of treatment); σb: locus-specific mutation rate in untreated 
individuals (no selection pressure); σt: locus-specific mutation rate 
in treated individuals (under selection pressure).
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Treatment scenarios and outcome measure
In our numerical evaluations of the model of a POCT 
detecting resistance mutations we varied the use of 
the POCT as a proportion of treated gonorrhoea infec-
tions from 0% to 100% and the assumed sensitivity 
and specificity of the test from 80 to 100%. If a POCT 
was used then gepotidacin was only used as a treat-
ment if no resistance mutations were detected. If no 
POCT was used then gepotidacin was used as a first-
line treatment.
We used stochastic simulations based on the deter-
ministic structure defined in Supplementary Material 1, 
Supplementary Text 2, Figure S1, Equations 2, Table S1, 
and a Gillespie algorithm to analyse model behaviour 
and predictions. We recorded the number of simula-
tions out of 100 replications in which the 5% resist-
ance threshold was reached at any time point over a 
five-year timeframe. (This corresponds to the WHO 
recommendation that when resistance to a specific 
antibiotic exceeds 5%, alternative antibiotics should 
be used [28].)  Table 2  lists parameter values used in 
simulations. A full list of parameter combinations used 
in each simulation scenario together with the results 
can be found in Supplementary Material 2.
Determining the prevalence of parC D86N in 
Europe and the United States
We obtained publicly available  N. gonorrhoeae  whole 
genome sequencing (WGS) data from the National 
Center for Biotechnology Information (NCBI) Sequence 
Read Archive deposited as part of the studies 
in  Supplementary Material 1, Supplementary Table 3. 
We ran FastQC [29] to assess WGS data quality and 
removed accessions with insufficient or poor-quality 
reads. We mapped reads to N. gonorrhoeae NCCP11945 
(NC_011035.1) using BWA-MEM vs 0.7.17-r1188 [30]. 
Duplicates were marked using Picard vs 2.8.0 (https://
github.com/broadinstitute/picard). We called vari-
ants using Pilon vs 1.23 [31] with minimum depth of 
10X and minimum mapping quality of 20. We removed 
accessions where more than 15% of sites were una-
ble to be called by Pilon due to insufficient cover-
age or poor mapping quality. We identified variants 
in  gyrA  and  parC  corresponding to the amino acid 
mutations gyrA A92T and parC D86N.
Currently, no published genomic databases report 
frequencies for the  gyrA  A92T mutation. The highest 
reported prevalence of the  parC  D86N mutation was 
38.6% of ciprofloxacin-resistant isolates [12]. We 
genotyped 10,259 unique accessions that passed our 
quality control filters. The frequencies of  parC  D86N 
and  gyrA  A92T mutations are low in Europe and 
in the United States (Euro-GASP:  parC  D86N 
1.8%, gyrA A92T 0% of all gonococcal isolates analysed 
September–November 2013 [32], GISP:  parC  D86N 
0.635%,  gyrA  A92T 0%, of all gonococcal isolates 
analysed 2000-2013 [33]). This means that in Europe 
Table 2
Parameter values used in simulation model
Model parameter (unit) Values used in individual simulations
Infection rate (per day) 5.56 × 10 
− 8, 1.67 × 10 − 8, 6.02 × 10 − 8, 2.28 × 10 − 7, 
2.29 × 10 − 7
Recovery rate f (inverse of duration of natural infection) (per day) 1/84, 1/160, 1/185, 1/240, 1/365
Treatment rate γ (inverse of time in days until patients first seek treatment) (per 
day) 1/3, 1/12, 1/13, 1/52
Cure rate for gepotidacin treatment, assuming double dose (inverse of 
treatment duration, i.e. time over MIC) (per day) 1.778 ( = 1/13.5h)
Cure rate for ciprofloxacin treatment, assuming single dose (inverse of 
treatment duration) (per day) 6 ( = 1/4h)
Proportion of patients that return for second round treatment p 1, 0.8, 0.6, 0.5
Mutation rate without treatment σb (substitutions per nt per day) 3.12 × 10
 − 9, 2.45 × 10 − 8
Mutation rate with treatment σt (substitutions per nt per day)
3.12 × 10 − 9, 2.45 × 10 − 8, 4.9 × 10 − 8, 1.23 × 10 − 7, 2.45 × 10 − 7, 
2.45 × 10 − 6, 2.45 × 10 − 5, 7.95 × 10 − 5, 9.66 × 10 − 4
Point-of-care test usage (%) 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Total simulated population 1.5 × 106
Initial number of infected individuals/equilibrium incidence rate 22,000
Initial prevalence of parC D86N (%) 0, 0.06, 0.18, 0.462, 0.669, 1.5, 2, 2.9, 3, 5.9, 6.5, 8.6, 13, 19.3, 38.6
Initial prevalence of gyrA A92T (%) 0, 1
Initial prevalence of double mutant (parC D86N/gyrA A92T) (%) 0
MIC: minimum inhibitory concentration.
All rates are per day. If more than one value is given, the whole range of values has been tested in different simulations. See Supplementary 
Material 2 for parameter combinations used in individual simulations. References and the basis of assumptions are included in 
the Supplementary Material 1, Supplementary Table 2.
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and the US simulation assuming 0.6–6.5% initial prev-
alence of parC D86N are the most applicable.
Ethical statement
No ethical approval was required for this study because 
no new data have been collected as part of the study.
 
Results
If the mutation rate with treatment is the same as with-
out treatment, then even a POCT usage of 20–30% 
can reduce the risk of resistance development (Figure 
2A). With assumptions of complete testing and perfect 
sensitivity and specificity, resistance did not develop 
in our simulations. If the initial prevalence of the step-
ping-stone mutations was lower than 6%, stochastic 
effects were important, so that even high POCT usage 
had little impact on the emergence of resistant strains 
(Supplementary Material 1, Supplementary Figure 1). In 
populations with an initial frequency of more than 6% 
of the parC D86N mutation, a POCT had a potential to 
reduce the risk of resistance reaching 5%. The effect of 
the POCT was roughly proportional to the usage level.
The greater the mutation rate during treatment and the 
higher the population prevalence of stepping-stone 
mutations, the higher the POCT usage needed to reduce 
the risk of resistance development (Figure 2). With an 
initial frequency of the parC D86N greater than 10% and 
a mutation rate during treatment of more than 1,000 
times the baseline mutation rate, POCT usage had to 
be 80–90% to halve the risk of resistance development 
(Figure 2G). An increase in mutation rate during treat-
ment of this order of magnitude is rarely observed 
in laboratory experiments (Supplementary Material 
1, Supplementary Table 4). If the initial prevalence 
of  gyrA  A92T is 1%, rather than 0%, more resistance 
emerges, especially if mutation rates under treatment 
are high (Supplementary Material 1, Supplementary 
Figure 2). If the mutation rate under treatment is less 
than 1,000 times the baseline mutation rate, the 
added risk of resistance development from  gyrA  A92T 
prevalence of 1% stays below 10%.
If there were no stepping-stone mutations in a popula-
tion, the risk of resistance development was generally 
Figure 2
Proportion of simulations in which the frequency of gepotidacin-resistant strains reaches 5% with different mutation rates, 
prevalence of parC D86N and POCT usage levels
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POCT: point-of-care testing.
The initial prevalence of gyrA A92T was 0 in all simulations. Mutation rates (substitutions per nt per day): A. 2.45 × 10 − 8, B. 4.9 × 10 − 8, C. 
1.23 × 10 − 7, D. 2.45 × 10 − 7, E. 2.45 × 10 − 6, F. 2.45 × 10 − 5, G. 7.95 × 10 − 5. Total number of simulations 100.
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low (< 5% if the prevalence of parC D86N was < 13% and 
only exceeding 25% if the prevalence of parC D86N was 
38.6%), and a POCT was only required if the mutation 
rate during treatment was very high (9.66 × 10-4 per site 
per day) (Supplementary Material 1, Supplementary 
Figures 1, 3). The sensitivity and specificity of the test 
did not have a great influence on the risk of resist-
ance development in the range tested. With high POCT 
usage (70–90%), a higher sensitivity (99% compared 
to 80%) of the test slightly decreases the probability 
of resistance spreading (Supplementary Material 1, 
Supplementary Figure 4).
parC D86N prevalence
We did not observe any isolates with  gyrA  A92T. We 
found that across all datasets 6.1% (626/10,259) of 
isolates encoded the parC D86N mutation. parC D86N 
was observed in 17 of 20 datasets.
If the mutation rate is not increased under treatment, 
the risk of resistance emergence is less than 5% in 
scenarios assuming 0.6 – 6.5% initial prevalence 
of parC D86N.
Discussion
Our results indicate that a molecular POCT detecting 
the two known stepping-stone mutations implicated 
in gepotidacin resistance could help reduce the risk of 
resistance development to gepotidacin, a novel anti-
biotic undergoing phase III trials, by  N. gonorrhoeae. 
The ability to do so would depend on the population 
prevalence of stepping-stone mutations and the muta-
tion rate under treatment. If both are low, then most 
strains will be sensitive to gepotidacin and a POCT 
would have a negligible effect on the risk of resistance 
development. If the mutation rate under treatment is 
very high and a large proportion of strains already have 
one stepping-stone mutation, a POCT would not be able 
to prevent resistance spreading, because resistance 
would arise too frequently after testing in previously 
sensitive infections. A high rate of horizontal gene 
transfer between coinfecting strains could equally lead 
to increased rates of resistance emergence [34]. It is 
possible that other fluoroquinolone resistance muta-
tions affect the MIC for gepotidacin in N. gonorrhoeae, 
but none have so far been identified.
This suggests that a POCT would be most valuable 
if the increase in mutation rate under treatment is 
moderate (no more than 100 times above the base-
line mutation rate) and the prevalence of pre-existing 
resistance mutations is at least 1%. In this case and if 
the prevalence of resistance mutations is not too high 
(maximum 13% in our analyses), even a 20–30% usage 
of the POCT could, given our assumptions, halve the 
risk of resistance development. This would be the case 
for all publicly available datasets we surveyed, where 
6.1% of all N. gonorrhoeae genomes carry parC D86N. 
However, due to stochastic variability, 50% usage 
would be preferable to reliably halve the risk of resist-
ance development. The prevalence of  parC  D86N is 
expected to vary among different countries. Therefore, 
optimum POCT usage values will be country-specific.
These results are in good agreement with a recent 
study which found that a POCT that detects resistance 
to three antibiotics used to treat gonorrhoea can pre-
vent resistant strains from spreading, if its usage is at 
least 37%, and that test sensitivity and specificity have 
a minor effect on resistance development [35]. Our 
study also agrees with results from Fingerhuth et al. 
according to which a POCT test with resistance detec-
tion prevents more cases of antibiotic-resistant gonor-
rhoea than a NAAT test without resistance detection, 
unless the POCT sensitivity is lower than 80% [36].
Since gepotidacin resistance only arises when both 
known stepping-stone mutations occur in the same 
strain, the relationship between the mutation rate 
under treatment and the risk of resistance development 
is not linear. Small increases in mutation rate of up to 
10-fold did not increase the risk of resistance develop-
ment in our simulations, unless the initial prevalence 
of  parC  D86N was assumed to be greater than 30%. 
If the mutation rate under treatment increased 1,000 
times or more, resistance almost always developed 
within 5 years.
Mutation rates during antibiotic exposure of this magni-
tude are rare according to the literature on other bacte-
rial species (Supplementary Material 1, Supplementary 
Table 4). Moreover, mutation rate measurements from 
in vitro experiments are prone to overestimation [37]. 
Our results suggest that estimates of the mutation rate 
under antibiotic exposure should be taken into account 
when evaluating treatment strategies. For example, 
Obolski and Hadany use a simulation model to show 
that in hospitals antibiotic mixing and cycling are supe-
rior to combination therapy, if bacterial mutagenesis is 
stress-induced [38].
We did not consider fitness costs of antibiotic resist-
ance mutations, because there is no population-level 
data on potential fitness costs of gepotidacin resist-
ance mutations. As fluoroquinolone-resistant strains 
persist in the population, we can assume that fitness 
costs associated with fluoroquinolone-resistance muta-
tions are small or absent [33]. Our model represents a 
worst-case scenario regarding the speed of spread of 
gepotidacin resistance. If there were sufficiently high 
fitness costs associated with one or both known step-
ping-stone mutations leading to gepotidacin resistance 
and a POCT could ensure that only infections without 
stepping-stone mutations were treated with gepotida-
cin, then newly-arising gepotidacin-resistant strains 
would potentially quickly become extinct [14].
Since some of the data for this study came from a 
relatively small sample (a phase II clinical trial), the 
evaluation may have to be updated when more data 
becomes available. In the case of treatment failure, 
the sequence in which alternative antibiotics are 
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prescribed can matter, especially if there is evidence 
for cross-resistance or resistance mutations to differ-
ent antibiotics for the same strains. Therapies with 
multiple targets, or antibiotics that require multiple 
mutations before they lose their efficacy, should be 
preferred as first-line treatments.
The main limitation of this study is the lack of empiri-
cal information on key model parameters. For exam-
ple, estimates for the duration of natural infection are 
based on limited observational studies from before 
1980. Similarly, the duration from infection to when 
patients seek treatment may vary among different 
populations. The population we model approximates 
an MSM population and likely overestimates treat-
ment rates for women who are more frequently asymp-
tomatic. However, as long as we compare simulation 
scenarios with the same sets of parameters, the quali-
tative outcome of our analysis is unlikely to change. 
Another limitation is that potentially we do not know 
all mechanisms of resistance to gepotidacin and we 
acknowledge the need for genomic surveillance to 
determine if other resistance mutations can arise.
Simulation studies can inform us on what data should 
be collected to improve treatment strategies. In the 
case of gepotidacin, molecular surveillance data to esti-
mate the frequency of known stepping-stone mutations 
is required. More generally, whole-genome surveillance 
data in combination with phenotypic antimicrobial sus-
ceptibility data can inform us about the frequency of 
resistance genes to other antimicrobials used for gon-
orrhoea treatment. In vitro or animal model experi-
ments could help to estimate the mutation rate under 
gepotidacin exposure. Mutation prevalence and rate 
should be considered when estimating the POCT usage 
required to reduce the risk of resistance development 
in a given population. Molecular POCTs for resistance 
mutations and stepping-stone mutations are likely to 
become important tools in antibiotic stewardship and 
surveillance in the coming years, and a combination of 
empirical study and modelling is required to optimise 
their use for public health benefit.
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